More than half (58% )of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to an Italian study. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of the Neurological Sciences. Aubagio is an oral disease-modifying therapy that has been…
Category: Industry News
Novel Early Intervention Study for Stroke Patients
MindMaze and The University of Auckland partner on novel early intervention study for stroke patients, expanding global breadth of research supporting the company’s brain tech solutions MindMaze, (digital therapeutics (DTx) for neurological recovery and care), in partnership with The University of Auckland, has announced a new interventional study that will aim to show the merits…
Trial failure for Jazz Pharmaceuticals’ cannabis-derived drug in MS
Jazz Pharmaceuticals nabiximols oromucosal spray did not meet the primary endpoint in a phase 3 trial, failing in its aim of improving Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21, as measured by the Modified Ashworth Scale (MAS). The spray is formulated from extracts of the cannabis sativa plant and contains tetrahydrocannabinol (THC) and…
Promising interim results for Ajovy
PEARL STUDY Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. 25th June 2022: Teva Pharmaceuticals Europe B.V. announced promising interim results from its Pan-European Real World study (PEARL),…
Brain-computer interface helps paralysed patient drive again
Almost ten years ago, Aldana Zuniga was paralysed from the waist down in a car accident. Now, a microchip implanted in his brain has helped him get behind the wheel of a car again. Using only his thoughts to control the speed, Zuniga drove laps in a NASCAR Cup racecar on a track in the…
Label Extension for Evrysdi®for Infants with SMA Under 2 Months Old
– Evrysdi is the first and only at-home administered treatment for patients living with SMA – Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date PTC Therapeutics, Inc. announced on May 31st 2022 that the US Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to…
Positive phase III data for Neurocrine’s Ingrezza in Huntington’s disease
Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing…
WFNR celebrates 25th anniversary
“Congratulations to the WFNR for all that it has achieved over the last 25 years. Today the WFNR is a true advocate for neurorehabilitation” said Professor David Good, WFNR President as the organisation celebrates its 25th anniversary. He continued: “We’re extremely grateful to all our members who have contributed to the success of the organisation…
Aphasia: guide to digital communication tools
News from The Stroke Association
